Last reviewed · How we verify
NCT05423769
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
trial testing Fingolimod in Relapsing-Remitting Multiple Sclerosis in 30 participants. Completed in 30 November 2023.
30 November 2023
Quick facts
| Lead sponsor | Hikma Pharmaceuticals LLC |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 19 January 2022 |
| Primary completion | 30 November 2023 |
| Estimated completion | 30 November 2023 |
| Sites | 2 locations across Egypt |
Drugs / interventions tested
- Fingolimod (FINGOLIMOD) — full drug profile →
Conditions studied
- Relapsing-Remitting Multiple Sclerosis — all drugs for Relapsing-Remitting Multiple Sclerosis →
Sponsor
Hikma Pharmaceuticals LLC — full company profile →
Who can join
18 and older, any sex, with Relapsing-Remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this observational study is to evaluate the Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients with Relapsing-Remitting Multiple Sclerosis in Egypt
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05423769
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fingolimod
Trials testing the same drug.
- NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
- NCT07220252 — Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis · Phase 2, PHASE3 · not yet recruiting
- NCT06408259 — Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relap · Phase 3 · recruiting
- NCT06087965 — Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage · Phase 1, PHASE2 · unknown
- NCT05123703 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Re · Phase 3 · active not recruiting
Other recruiting trials for Relapsing-Remitting Multiple Sclerosis
Currently open trials in the same condition.
- NCT05123703 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Re · Phase 3 · active not recruiting
- NCT05090371 — A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation · Phase 4 · active not recruiting
- NCT04530318 — Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis · Phase 2 · active not recruiting
Other Hikma Pharmaceuticals LLC trials
Trials by the same sponsor.
- NCT06326697 — Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) · Phase 1 · completed
- NCT05563818 — Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia · completed
- NCT04468165 — Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical · completed
- NCT03625388 — Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia · Phase 2 · completed
- NCT03452501 — Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05423769 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hikma Pharmaceuticals LLC
- Last refreshed: 23 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05423769.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing